Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.61 |
| ▸ | FDPS | P14324 | 2/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CCR9 | P51686 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18247738 | 0.82 | FDPS (0.49) | CCR2FDPSGPR35MCL1ALDH1A1 | |
| SCHEMBL19332484 | 0.81 | GPR35 (0.50) | CCR2FDPSGPR35ALDH1A1CYP1A2 | |
| SCHEMBL28720908 | 0.79 | FDPS (0.47) | CCR2FDPSGPR35MCL1ALDH1A1 | |
| SCHEMBL19921311 | 0.79 | CCR2 (0.65) | CCR2FDPSGPR35MCL1ALDH1A1 | |
| SCHEMBL7993476 | 0.77 | CCR2 (0.64) | CCR2FDPSGPR35MCL1ALDH1A1 | |
| SCHEMBL28844727 | 0.76 | CCR2 (0.51) | CCR2FDPSMCL1ALDH1A1DAO | |
| SCHEMBL6302433 | 0.76 | CCR2 (1.00) | CCR2 | |
| SCHEMBL12466600 | 0.76 | CCR2 (0.61) | CCR2GPR35ALDH1A1POLB | |
| SCHEMBL30067600 | 0.74 | CCR2 (0.69) | CCR2FDPSGPR35MCL1ALDH1A1 | |
| SCHEMBL701976 | 0.74 | CCR2 (0.69) | CCR2FDPSGPR35MCL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298003-B1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2023-04-19 | — | — | EP | disclosed |
| CN-107849015-B | Benzimidazole derivatives as PAD4 inhibitors | 葛兰素知识产权发展有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-20200095227-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-26 | — | — | US | disclosed |
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
| US-20180297983-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-18 | — | — | US | disclosed |
| EP-3298003-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016185279-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297983-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | PADI4, PADI1, PADI2 | CCR2 958/4885FDPS 2228/4885GPR35 2793/4885 |
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | CCR2 958/4885FDPS 2228/4885GPR35 2793/4885 |
| US-20200095227-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | PADI4, PADI1, PADI2 | CCR2 958/4885FDPS 2228/4885GPR35 2793/4885 |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | CCR2 958/4885FDPS 2228/4885GPR35 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.